Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Baseline tumor and treatment characteristics

From: Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors

  Primary lung cancer Metastatic lung tumor Total
Number 172 tumors 57 tumors 229 tumors
Tumor diameter (cm)    2.2 (range: 0.9-4.7)
  ≤ 2.0 73 (42%) 27 (47%) 100 (43%)
  2.1-3.0 75 (43%) 23 (40%) 98 (42%)
  3.1-5.0 24 (13%) 7 (12%) 31 (13%)
Tumor appearance    
  Mainly solid component 160 (93%) 57 (100%) 217 (94%)
  Mainly ground-glass opacity 12 (6%) 0 (0%) 12 (5%)
SUVmax on staging FDG-PET    5.9 (range: 0.6-22.8)
  < 5.9 53 (50%) 4 (57%) 57 (50%)
  ≥ 5.9 53 (50%) 3 (42%) 56 (50%)
Prescription dose    
  BED10 ≤ 105 Gy 84 (48%) 12 (21%) 96 (41%)
  BED10 > 105 Gy 88 (51%) 45 (78%) 133 (58%)
Date of treatment    
  2001-2005 76 (44%) 39 (68%) 115 (50%)
  2006-2011 96 (55%) 18 (31%) 114 (50%)
  1. Abbreviations: SUVmax maximum standardized uptake value, FDG-PET [18F]fluorodeoxyglucose positron emission tomography, BED10 biological effective dose calculated using α/β = 10.